검색어 : 통합검색[Swanson Cooper]
총 192건 중 192건 출력
, 16/20 페이지
-
151
- P-600. Efficacy of a Bivalent RSVpreF Vaccine in Older Adults Across a Second RSV Season
- Walsh, Edward E; Woodside, John; Perez Marc, Gonzalo; Eiras, Daniel P; Jiang, Qin; Llapur, Conrado J; Fukushima, Yasushi; Rä met, Mika; Bont, Louis J; Hussen, Nazreen; Mikati, Tarek; Patton, Michael; Zareba, Agnieszka; Ilangovan, Kumar; Maddalena Lino, Maria; Kalinina, Elena; Cooper, David; Swanson, Kena A; Anderson, Annaliesa S; Gurtman, Alejandra C; Munjal, Iona; University of Rochester , Rochester, NY; Pfizer , London, England ,; i-trials , Buenos Aires, Ciudad Autonoma de Buenos Aires ,; Pfizer, Inc. , Pearl River, New York; Pfizer , London, England ,; Hospital del Niñ o Jesú s , San Miguel de Tucuman, Tucuman ,; Fukuwa clinic , Chuo-ku, Tokyo ,; Tampere University , Tampere, Pirkanmaa ,; University Medical Centre Utrecht , Utrecht, Utrecht ,; Netcare Lakeview Hospital , Benoni, Gauteng ,; 3. Pfizer, Inc., Vaccine Research & Development , Pearl River, New York; Pfizer, Vaccine Research and Development , Hurley, England ,; Pfizer , London, England ,; Vaccine Research and Development , Pfizer , , Raleigh, North Carolina; Pfizer , London, England ,; Pfizer , London, England ,; Pfizer , London, England ,; Pfizer , London, England ,; Pfizer , London, England ,; Pfizer , London, England ,; Pfizer Inc; (Open forum infectious diseases, v.12, 2025, pp.ofae631.798)
-
152
- P-600. Efficacy of a Bivalent RSVpreF Vaccine in Older Adults Across a Second RSV Season
- Edward E Walsh; John Woodside; Gonzalo Perez Marc; Daniel P Eiras; Qin Jiang; Conrado J Llapur; Yasushi Fukushima; Mika Rämet; Louis J Bont; Nazreen Hussen; Tarek Mikati; Michael Patton; Agnieszka Zareba; Kumar Ilangovan; Maria Maddalena Lino; Elena Kalinina; David Cooper; Kena A Swanson; Annaliesa S Anderson; Alejandra C Gurtman; Iona Munjal; University of Rochester , Rochester, NY; Pfizer , London, England ,; i-trials , Buenos Aires, Ciudad Autonoma de Buenos Aires ,; Pfizer, Inc. , Pearl River, New York; Pfizer , London, England ,; Hospital del Niño Jesús , San Miguel de Tucuman, Tucuman ,; Fukuwa clinic , Chuo-ku, Tokyo ,; Tampere University , Tampere, Pirkanmaa ,; University Medical Centre Utrecht , Utrecht, Utrecht ,; Netcare Lakeview Hospital , Benoni, Gauteng ,; 3. Pfizer, Inc., Vaccine Research & Development , Pearl River, New York; Pfizer, Vaccine Research and Development , Hurley, England ,; Pfizer , London, England ,; Vaccine Research and Development , Pfizer , , Raleigh, North Carolina; Pfizer , London, England ,; Pfizer , London, England ,; Pfizer , London, England ,; Pfizer , London, England ,; Pfizer , London, England ,; Pfizer , London, England ,; Pfizer Inc; (Open Forum Infectious Diseases, v., 2025, )
-
153
- 1634. Respiratory Syncytial Virus-Associated Health Care Utilization in the Pivotal Phase 3 Trial RSV Vaccine Efficacy Study In Older Adults Immunized Against RSV Disease (RENOIR)
- Walsh, Edward E; Ilangovan, Kumar; Zareba, Agnieszka; Jiang, Qin; Marc, Gonzalo Pé rez; Verbeek, Tjitte; Breedt, Johannes; Stacey, Helen; Uchiyama, Akiyoshi; Ojanperä , Jussi; DeHaan, Elliot N; Patton, Michael; Kan, Yanqing; Eiras, Daniel P; Mikati, Tarek; Kalinina, Elena; Cooper, David; Anderson, Annaliesa S; Swanson, Kena A; Gruber, William C; Gurtman, Alejandra C; Schmoele-Thoma, Beate; University of Rochester , Rochester, NY; Pfizer, Vaccine Research and Development , Raleigh, North Carolina; Pfizer, Pearl RIver, New York; Pfizer, Pearl RIver, New York; Hospital Militar Central de Buenos Aires , Ciudad Autó noma de Buenos Aires, Buenos Aires , Argentina; Huisartsenpraktijk Radesingel , Radesingel, Groningen , Netherlands; Emmed Research , Pretoria, Gauteng , South Africa; Diablo Clinical Research , Walnut Creek, California; Medical Corporation Asbo , Tokyo Asbo Clinic, Kyobashi Chuo-ku, Tokyo , Japan; Terveystalo Jyvä skylä , Jyvä skyla, Keski-Suomi , Finland; Pfizer, Pearl RIver, New York; Pfizer, Vaccine Research and Development , Raleigh, North Carolina; Pfizer, Pearl RIver, New York; Pfizer, Inc. , Pearl River, New York; 3. Pfizer, Inc., Vaccine Research & Development , Pearl River, N; (Open forum infectious diseases, v.10, 2023, pp.ofad500.1468)
-
154
- Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
- Mulligan, Mark J.; Lyke, Kirsten E.; Kitchin, Nicholas; Absalon, Judith; Gurtman, Alejandra; Lockhart, Stephen; Neuzil, Kathleen; Raabe, Vanessa; Bailey, Ruth; Swanson, Kena A.; Li, Ping; Koury, Kenneth; Kalina, Warren; Cooper, David; Fontes-Garfias, Camila; Shi, Pei-Yong; Tü reci, Ö zlem; Tompkins, Kristin R.; Walsh, Edward E.; Frenck, Robert; Falsey, Ann R.; Dormitzer, Philip R.; Gruber, William C.; Ş ahin, Uğ ur; Jansen, Kathrin U.; ; (Nature, v.586, 2020, pp.589-593)
-
155
- Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
- Mulligan, Mark J.; Lyke, Kirsten E.; Kitchin, Nicholas; Absalon, Judith; Gurtman, Alejandra; Lockhart, Stephen; Neuzil, Kathleen; Raabe, Vanessa; Bailey, Ruth; Swanson, Kena A.; Li, Ping; Koury, Kenneth; Kalina, Warren; Cooper, David; Fontes-Garfias, Camila; Shi, Pei-Yong; Tü reci, Ö zlem; Tompkins, Kristin R.; Walsh, Edward E.; Frenck, Robert; Falsey, Ann R.; Dormitzer, Philip R.; Gruber, William C.; Ş ahin, Uğ ur; Jansen, Kathrin U.; ; (Nature, v.590, 2021, pp.E26-E26)
-
156
- Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds
- Simõ es, Eric A F; Klein, Nicola P; Sabharwal, Charu; Gurtman, Alejandra; Kitchin, Nicholas; Ukkonen, Benita; Korbal, Piotr; Zou, Jing; Xie, Xuping; Sarwar, Uzma N; Xu, Xia; Lockhart, Stephen; Cunliffe, Luke; Lu, Claire; Ma, Hua; Swanson, Kena A; Koury, Kenneth; Shi, Pei-Yong; Cooper, David; Tü reci, Ӧ zlem; Jansen, Kathrin U; Ş ahin, Uğ ur; Gruber, William C; Children’s Hospital Colorado and University of Colorado School of Medicine , Aurora, CO , USA; Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California , Oakland, CA , USA; Vaccine Research and Development, Pfizer Inc , Pearl River, NY , USA; Vaccine Research and Development, Pfizer Inc , Pearl River, NY , USA; Vaccine Research and Development, Pfizer Ltd , Hurley , UK; Espoo Vaccine Research Clinic, Tampere University , Espoo , Finland; Oś rodek Badań Klinicznych In-Vivo , Bydgoszcz− Toruń , Poland; Department of Biochemistry and Molecular Biology, University of Texas Medical Branch , Galveston , TX , USA; Department of Biochemistry and Molecular Biology, University of Texas Medical Branch , Galveston , TX , USA; (Journal of the Pediatric Infectious Diseases Society, v.12, 2023, pp.234-238)
-
157
- Specifying and Sustaining Pigmentation Patterns in Domestic and Wild Cats
- Kaelin, Christopher B.; Xu, Xiao; Hong, Lewis Z.; David, Victor A.; McGowan, Kelly A.; Schmidt-Kü ntzel, Anne; Roelke, Melody E.; Pino, Javier; Pontius, Joan; Cooper, Gregory M.; Manuel, Hermogenes; Swanson, William F.; Marker, Laurie; Harper, Cindy K.; van Dyk, Ann; Yue, Bisong; Mullikin, James C.; Warren, Wesley C.; Eizirik, Eduardo; Kos, Lidia; O’Brien, Stephen J.; Barsh, Gregory S.; Menotti-Raymond, Marilyn; HudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, USA.; Laboratory of Genomic Diversity, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.; Department of Genetics, Stanford University, Stanford, CA, 94305, USA.; Laboratory of Genomic Diversity, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.; Department of Genetics, Stanford University, Stanford, CA, 94305, USA.; Laboratory of Genomic Diversity, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.; Laboratory of Genomic Diversity, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.; Department of Biological Sciences, Florida International University, Miami, FL 33199, USA.; Laboratory of Genomic Diversity, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.; HudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, USA.; Department of Genetics, Stanford University, Stanford, CA, 94; (Science, v.337, 2012, pp.1536-1541)
-
158
- SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
- Falsey, Ann R.; Frenck Jr., Robert W.; Walsh, Edward E.; Kitchin, Nicholas; Absalon, Judith; Gurtman, Alejandra; Lockhart, Stephen; Bailey, Ruth; Swanson, Kena A.; Xu, Xia; Koury, Kenneth; Kalina, Warren; Cooper, David; Zou, Jing; Xie, Xuping; Xia, Hongjie; Tü reci, Ö zlem; Lagkadinou, Eleni; Tompkins, Kristin R.; Shi, Pei-Yong; Jansen, Kathrin U.; Ş ahin, Uğ ur; Dormitzer, Philip R.; Gruber, William C.; University of Rochester, Rochester, NY; Cincinnati Children’s Hospital, Cincinnati, OH; University of Rochester, Rochester, NY; Pfizer Vaccine Research and Development, Hurley, United Kingdom; Pfizer Vaccine Research and Development, Pearl River, NY; Pfizer Vaccine Research and Development, Pearl River, NY; Pfizer Vaccine Research and Development, Hurley, United Kingdom; Pfizer Vaccine Research and Development, Hurley, United Kingdom; Pfizer Vaccine Research and Development, Pearl River, NY; Pfizer Vaccine Research and Development, Collegeville, PA; Pfizer Vaccine Research and Development, Pearl River, NY; Pfizer Vaccine Research and Development, Pearl River, NY; Pfizer Vaccine Research and Development, Pearl River, NY; University of Texas Medical Branch, Galveston, TX; University of Texas Medical Branch, Galveston, TX; University of Texas Medical Branch, Galveston, TX; BioNTech, Mainz, Germany; BioNTech, Mainz, Germany; Pfizer Vaccine Research and Development, Pear; (The New England journal of medicine, v.385, 2021, pp.1627-1629)
-
159
- RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
- Walsh Edward E.; Frenck Robert; Falsey Ann R.; Kitchin Nicholas; Absalon Judith; Gurtman Alejandra; Lockhart Stephen; Neuzil Kathleen; Mulligan Mark J; Bailey Ruth; Swanson Kena A; Li Ping; Koury Kenneth; Kalina Warren; Cooper David; Fontes-Garfias Camila; Shi Pei-Yong; Türeci Özlem; Thompkins Kristin R; Lyke Kirsten E.; Raabe Vanessa; Dormitzer Philip R; Jansen Kathrin U; Sahin Uğur; Gruber William C.; ; (, v., 2020, )
-
160
- Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report
- Mulligan Mark J.; Lyke Kirsten E.; Kitchin Nicholas; Absalon Judith; Gurtman Alejandra; Lockhart Stephen P.; Neuzil Kathleen; Raabe Vanessa; Bailey Ruth; Swanson Kena A.; Li Ping; Koury Kenneth; Kalina Warren; Cooper David; Fonter-Garfias Camila; Shi Pei-Yong; Tuereci Ozlem; Tompkins Kristin R.; Walsh Edward E.; Frenck Robert; Falsey Ann R.; Dormitzer Philip R.; Gruber William C.; Sahin Ugur; Jansen Kathrin U.; ; (, v., 2020, )
QUICK MENU
